Levi & Korsinsky announces it has commenced an investigation of Cempra, Inc. ("Cempra" or the "Company") (NASDAQ: CEMP) concerning possible violations of federal securities laws by certain officers and directors. On November 2, 2016, the U.S. Food and Drug Administration posted a preliminary review on its website of Cempra's drug, solithromycin, highlighting a significant safety signal for hepatotoxicity. Upon this news, shares of Cempra fell over 60% during intraday trading. To obtain additional information about the investigation, go to: http://zlk.9nl.com/cempra-cemp or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.